São Paulo State University (UNESP), School of Pharmaceutical Sciences, Tuberculosis Research Laboratory, Araraquara, São Paulo, CEP 14800-903, Brazil; Universidad Católica de Santa María, Vicerrectorado de Investigación, Facultad de Ciencias Farmacéuticas Bioquímicas y Biotecnológicas, Brazil.
Laboratory of Nanobiotechnology, Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
Eur J Med Chem. 2022 Nov 5;241:114640. doi: 10.1016/j.ejmech.2022.114640. Epub 2022 Aug 9.
Nanobiotechnology is a relatively unexplored area that has, nevertheless, shown relevant results in the fight against some diseases. Antimicrobial peptides (AMPs) are biomacromolecules with potential activity against multi/extensively drug-resistant bacteria, with a lower risk of generating bacterial resistance. They can be considered an excellent biotechnological alternative to conventional drugs. However, the application of several AMPs to biological systems is hampered by their poor stability and lifetime, inactivating them completely. Therefore, nanotechnology plays an important role in the development of new AMP-based drugs, protecting and carrying the bioactive to the target. This is the first review article on the different reported nanosystems using AMPs against bacteria listed on the WHO priority list. The current shortage of information implies a nanobiotechnological potential to obtain new drugs or repurpose drugs based on the AMP-drug synergistic effect.
纳米生物技术是一个相对未被探索的领域，但在对抗某些疾病方面已经显示出相关的结果。抗菌肽（AMPs）是具有潜在活性的生物大分子，可对抗多药/广泛耐药菌，产生细菌耐药性的风险较低。它们可以被认为是传统药物的一种极好的生物技术替代品。然而，由于其稳定性和半衰期差，几种 AMP 应用于生物系统受到阻碍，完全使它们失活。因此，纳米技术在开发新的基于 AMP 的药物方面发挥着重要作用，保护和携带生物活性物质到达靶标。这是第一篇关于世界卫生组织优先名单上报道的不同基于 AMP 的纳米系统对抗细菌的综述文章。目前信息的缺乏意味着纳米生物技术具有获得新药或基于 AMP-药物协同作用重新利用药物的潜力。
